A Randomized, Open Label, Parallel Group, Regional, Multicenter, Phase III Study of Oral Gefitinib (Iressa) Versus Intravenous Docetaxel (Taxotere) in Patients With Locally Advanced or Metastatic Recurrent Non Small Cell Lung Cancer Who Have Previously Received Platinum Based Chemotherapy (ISTANA)

Trial Profile

A Randomized, Open Label, Parallel Group, Regional, Multicenter, Phase III Study of Oral Gefitinib (Iressa) Versus Intravenous Docetaxel (Taxotere) in Patients With Locally Advanced or Metastatic Recurrent Non Small Cell Lung Cancer Who Have Previously Received Platinum Based Chemotherapy (ISTANA)

Completed
Phase of Trial: Phase III

Latest Information Update: 05 Jun 2012

At a glance

  • Drugs Docetaxel; Gefitinib
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms ISTANA
  • Sponsors AstraZeneca
  • Most Recent Events

    • 09 Feb 2010 Results published in Clinical cancer research: an official journal of the American Association for Cancer Research.
    • 12 May 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 23 Sep 2008 Status changed from completed to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top